

**Table S7**

Sensitivity analyses for comparison of aflibercept and ranibizumab

<b>Subgroup – functional and anatomical outcome</b>		<b>Before switch</b>	<b>After switch</b>
<b>Aflibercept to bevacizumab</b> (n=32)	<b>Visual acuity [in LogMAR]</b>	0.45	0.60
	<b>CRT [in <math>\mu\text{m}</math>]</b>	303.8	335.9
	<b>Macular volume [in <math>\text{mm}^3</math>]</b>	7.9	8.2
<b>Ranibizumab to bevacizumab</b> (n=33)	<b>Visual acuity [in LogMAR]</b>	0.68	0.76
	<b>CRT [in <math>\mu\text{m}</math>]</b>	316.1	336.0
	<b>Macular volume [in <math>\text{mm}^3</math>]</b>	8.2	8.3

  

<b>Subgroup – treatment interval</b>		<b>Days</b>
<b>Aflibercept to bevacizumab</b> (n=32)	<b>Before switch</b>	38.6
	<b>After switch (initial)<sup>a</sup></b>	32.1
	<b>After switch</b>	41.8
<b>Ranibizumab to bevacizumab</b> (n=33)	<b>Before switch</b>	39.4
	<b>After switch (initial)<sup>a</sup></b>	33.5
	<b>After switch</b>	37.9

<sup>a</sup>after switch (initial), interval between first and second injection<sup>b</sup>after switch, interval between penultimate and last injection

